Key result
The Trifecta bioprosthetic valve provided significantly lower mean pressure gradient (8.6 vs. 13.3 mmHg) and larger effective orifice area index than the Magna valve in Japanese patients.
Why the study?
Does the Trifecta bioprosthetic valve improve early postoperative hemodynamic performance compared to the Magna valve in Japanese patients undergoing aortic valve replacement?
Cohort (n=74)
No
Does the Trifecta bioprosthetic valve improve early postoperative hemodynamic performance compared to the Magna valve in Japanese patients undergoing aortic valve replacement?
Absolute Event Rate: 8.6% vs 13.3%
p-value: p=0.001
The Trifecta bioprosthetic valve provides superior early postoperative hemodynamic performance compared to the Magna valve in Japanese patients, particularly benefiting those with a small annulus size relative to body size.
No takes yet. Share an insight, caveat, or question.
May support Trifecta in small-annulus Japanese patients; leaves open randomized confirmation of durability and outcomes.
Maruyama et al. (2014) conducted a cohort in Aortic valve disease (n=74). Trifecta bioprosthetic valve vs. Magna bioprosthetic valve was evaluated on Postoperative mean pressure gradient (MPG) (p=0.001). The Trifecta bioprosthetic valve provided significantly lower mean pressure gradient (8.6 vs. 13.3 mmHg) and larger effective orifice area index than the Magna valve in Japanese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: